CTRI/2023/01/049286已完成3 期
A Multicentric, Randomized, Prospective, Open label, Parallel Group, Active Controlled, Comparative and Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC Dapagliflozin 10 mg Gliclazide 60 mg SR tablet in Patients with Type 2 Diabetes Mellitus who are inadequately controlled on Metformin Monotherapy.
Eris Life Sciences Limited11 个研究点 分布在 1 个国家目标入组 244 人开始时间: 2023年1月2日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 244
- 试验地点
- 11
- 主要终点
- 1.Adjusted Mean Change from Baseline in glycated Haemoglobin A1c
研究概览
简要总结
This trial is a phase III, prospective, randomized, Open Label, comparative, parallel group, multicenter clinical study to evaluate the efficacy, safety and tolerability of FDC Dapagliflozin 10mg Gliclazide 60mg SR with concomitant administration of Reference Product Dapagliflozin 10mg in patients with type 2 diabetes mellitus inadequately controlled on Metformin monotherapy. After confirming the inclusion/exclusion criteria the subject will be randomized and provided with study medication at randomization visit. Subjects will be provided with diary at randomization visit, which need to be brought along with in each subsequent visit till the last visit. Follow up visits will be done on week 4/day 28(±2), week 8/day 56(±2), week 12/day 84 ,Week 16 (End of Treatment) visit to assess efficacy, safety and tolerability.
Total number of subjects enrolled in the study are 244 each arm consist 122 subjects. 122 subjects will receive intervention and 122 subjects will receive reference.Treatment will be given to patients for 16 weeks and follow up after one week.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Willing to give written informed consent to participate 2.Both genders (Male and Female) Age: 18-65 years both inclusive 3.Women of childbearing potential who comply to use an adequate method of contraception to avoid pregnancy throughout the study & who have a negative urine pregnancy test.
- •4.BMI: <35.0 kg/m2 5.HbA1c: ≥8.0% to ≤10.0% 6.In Patients with Type 2 Diabetes Mellitus who are inadequately controlled on Metformin Monotherapy ≥1000 mg per day for at least 3 months and having inadequate glycemic control 7.Patients willing to comply with the protocol requirements.
排除标准
- •1.History of unstable or rapidly progressing renal disease 2.History of Type 1 diabetes mellitus 3.Patients with FPG ≥270mg/dl at screening to be excluded 4.Macroalbuminuria; defined as albumin-creatinine ratio of >500mg/g.
- •5.Estimated GFR <60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation) 6.Current/chronic use of the following medication: thiazolidinedione (TZD), SU derivative, Glucagon like peptide 1 receptor agonist (GLP-1RA), (dipeptidyl peptidase 4 inhibitor) DPP-4I, SGLT-2 inhibitors, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).
- •Subjects on diuretics will only be excluded when these drugs cannot be stopped for the duration of the study.
- •7.Volume depleted patients.
- •Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.
- •8.Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e., sports injury, headache, or back ache).
- •However, no such drugs can be taken within a timeframe of 2 weeks prior to renal testing 9.Current urinary tract infection and active nephritis 10.Recent (<6 months) history of cardiovascular disease, including: 1 Acute coronary syndrome 2 Chronic heart failure (New York Heart Association grade II-IV) 3 Stroke or transient ischemic neurologic disorder 11.Complaints compatible with neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan) 12.Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN 13.(Unstable) thyroid disease; defined as free thyroxine (fT4) outside of laboratory reference values or change in treatment within 3 months prior to screening visit 14.History of or actual malignancy (except basal cell carcinoma) Active cancer personal history of cancer within 5 years.
- •History of or actual severe mental disease (Have any other condition including drug or alcohol abuse or psychiatric disorder including dementia that precludes the participant from following and completing the protocol as per judgement of the investigator.) Substance abuse (alcohol: defined as >4 units/day) 15.Allergy to any of the agents used in the study 16.Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study.
- •17.Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.
- •18.History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
- •19.Severe uncontrolled hypertension defined as SBP ≥150 mmHg and/or Diastolic Blood Pressure (DBP) ≥100 mmHg 20.Inability to understand the study protocol or give informed consent 21.If participated in any other clinical trial within 6 months before the current study or concurrently enrolled/scheduled to be enrolled in any other type of medical research during the current study period.
- •22.Undergone a surgical procedure within 4 weeks prior to signing informed consent form.
结局指标
主要结局
1.Adjusted Mean Change from Baseline in glycated Haemoglobin A1c
时间窗: Baseline to Week 16.
(HbA1c) at Week 16.
时间窗: Baseline to Week 16.
次要结局
- 1. Adjusted Mean Change from Baseline in Fasting Plasma Glucose (FPG) at Week 16.(2. Mean change in fasting plasma glucose (FPG) from baseline to end of the study visit (16 Weeks).)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
The Efficacy and Safety of Triamcinolone Acetonide 0.1% w/w and Lignocaine Hydrochloride 2.0% w/w Oromucosal Gel in Patients with Mouth Ulcers.CTRI/2020/09/027952Abbott Healthcare Pvt Ltd112
已完成
3 期
A 12-week study to determine efficacy and safety of Glycopyrronium Formoterol combination through dry powder inhaler in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2017/08/009286Cipla Ltd360
已完成
3 期
A clinical trial to assess the efficacy and safety of recombinant insulin glargine compared with Lantus® in patients with Type II Diabetes Mellitus uncontrolled on OAD Therapy.CTRI/2010/091/000012LG Life Sciences India Pvt Ltd278
Unknown
3 期
Immunotherapy With Racotumomab in Advanced Lung CancerLung Cancer, Non-small CellNSCLCNCT01460472Recombio SL1,082
已完成
3 期
Phase III trial of FDC of arterolane maleate and PQP tablets in patients with acute uncomplicated Plasmodium vivax malariaCTRI/2011/11/002129Ranbaxy Laboratories Limited316